Journal: Biomedical Reports
Article Title: Targeting ULK1 and USP20 to modulate autophagy and chemosensitivity in cancer cell lines
doi: 10.3892/br.2026.2124
Figure Lengend Snippet: Changes in the basal autophagy flux in different cancer cell lines in response to doxorubicin. HepG2, MCF-7, MDA-MB-231, U87 and normal fibroblast cells were treated with different concentrations of doxorubicin chemotherapy. The level of expression of ULK1, USP20, and P62 was determined via reverse transcription-quantitative PCR. (A-C) Relative expression of ULK1, USP20 and P62 in HepG2 cells. (D-F) Relative expression of ULK1, USP20 and P62 in MCF-7 breast cancer cells. (G-I) Relative expression of ULK1, USP20 and P62 in MDA-MB-231 breast cancer cells. (J-L) Relative expression of ULK1, USP20 and P62 in U87 cells. (M-O) Relative expression of ULK1, USP20 and P62 in normal fibroblast cells. Three repeats were considered for each treatment group. Data are presented as the mean ± SEM. Statistical significance was indicated as * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001 (one-way ANOVA followed by Bonferroni's multiple comparisons post hoc test). ULK1, Unc-51-like kinase 1.
Article Snippet: The following cell lines were involved in the present study and provided from The American Type Culture Collection, human pancreatic cancer cell line PANC-1 (CRL-1469 TM ), Human lung carcinoma-A549 (CRM-CCL-185 TM ), human glioblastoma of unknown origin U-87 MG (HTB-14 TM ), human liver cancer HepG2 (HB-8065 TM ), human breast carcinoma MCF7 (HTB-22 TM ), human breast adenocarcinoma MDA-MB-231 (CRM-HTB-26 TM ), and human normal primary non-immortalized dermal fibroblasts-HDFa (PCS-201-012, https://www.atcc.org/products/pcs-201-012 ).
Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction